Thus, in our opinion LAT1-inhibitors are most likely not effective enough alone, if not used in combinations with other chemotherapeutics that simultaneously affect other critical targets of the cancer cells or with agents that can block the compensating amino acid supply, such as aminopeptidase inhibitor, bestatin. Here, SLC7A5 is linked to cancer.